Oxford University says ‘there are no safety concerns’ in the testing but will wait for additional data before restarting.
Oxford University said on Tuesday it halted a small UK trial to test the COVID-19 vaccine it developed alongside AstraZeneca in children and teenagers, as they are Wait for more data on rare coagulation problems in vaccinated adults.
The university, which helped develop the combined vaccine, said in a statement that there were “no safety concerns” in the trial, but acknowledged concerns about a potential link to blood clots. by saying they are waiting for additional data from the UK Health Care and Drug Administration (MHRA) before resuming the study.
“Parents and kids should continue to attend all scheduled visits and be able to contact the test site if they have any questions,” it added.
This is AstraZeneca’s latest hit drama, which has caused controversy about not delivering the promised doses of the drug to the European Union, as well as about the effectiveness and safety of the jab.
The MHRA is one of several globally that analyzes real-world data from AstraZeneca implementations to see if there is a sure link between the stab strike and a rare form of blood clot, after the cases. Originally reported in Norway and mainland Europe.
MHRA reported over the weekend that there were 30 cases of blood clots, 7 deaths, out of 18 million doses used in the UK.
The European Medicines Agency (EMA) on Tuesday said it “has yet to come to a conclusion and a review is currently underway”.
EU Health Commissioner Stella Kyriakides later said that the agency is expected to make its decision “by the end of Wednesday”, adding that she is “closely linked” with the EMA.
Germany and France have both restricted the use of vaccines to the elderly because of fears that younger people are at greater risk of blood clots.
‘Benefits outweigh risks’
The UK and vaccine developers have so far resisted any restrictions on vaccine use, saying there is no evidence of any association.
Adam Finn, professor of pediatrics at the UK’s Bristol University, says the benefits continue to outweigh the risks.
“We need to know more about those affected and we need to understand exactly how the diseases happened,” he said.
“If you are currently being given a dose of Oxford-AstraZeneca vaccine, your chances of survival will increase if you take the vaccine and will decrease if not,” he added.
The World Health Organization said on Tuesday there is no reason to change its assessment that the benefits of the AstraZeneca vaccine against COVID-19 outweigh any risks.
Exchanges with governments across Europe over the production, supply, possible side effects and the value of the vaccine kept the Anglo-Swedish drugmaker on hold for months. .